Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma

Zhang,Jue; Xu,Meng; Gao,Han; Guo,Jin‑Chen; Guo,Yu‑Lin; Zou,Miao; Wu,Xu‑Feng

doi:10.3892/ol.2018.7778

Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma

Authors:
- Jue Zhang
- Meng Xu
- Han Gao
- Jin‑Chen Guo
- Yu‑Lin Guo
- Miao Zou
- Xu‑Feng Wu
View Affiliations

Affiliations: Department of Gynecology, Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei 430070, P.R. China, Shantou University Medical College, Shantou, Guangdong 515041, P.R. China
Published online on: January 12, 2018 https://doi.org/10.3892/ol.2018.7778
Pages: 3669-3675
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the seventh most common type of cancer and the eighth most common cause of cancer-associated mortality among women. A number of studies have hypothesized that the expression status of certain genes may be used to predict prognosis in ovarian cancer. In the present study, the RNA expression data from next‑generation sequencing and the clinical information of 413 patients from The Cancer Genome Atlas dataset was downloaded to identify the association between gene‑expression level and the survival time of the patients with ovarian serous cystadenocarcinoma. A five‑gene model was predicted to be significantly associated with patient survival in ovarian serous cystadenocarcinoma by using random survival forests variable hunting algorithm and Cox analysis. A total of two genes, mesencephalic astrocyte‑derived neurotrophic factor and dedicator of cytokinesis 11, of the predicted five genes demonstrated positive expression in the ovarian serous cystadenocarcinoma cancer tissues by polymerase chain reaction analysis. Kaplan‑Meier and Receiver Operating Characteristic analysis confirmed that the model of the two genes exhibited high sensitivity and specificity to predict the prognostic survival of patients. In conclusion, the expression of the two genes in the two‑gene model was associated with the prognostic outcomes of patients with ovarian serous cystadenocarcinoma; the model demonstrated potential as a novel prognostic indicator, which may have important clinical significance.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
3	Klint A, Tryggvadóttir L, Bray F, Gislum M, Hakulinen T, Storm HH and Engholm G: Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 49:632–643. 2010. View Article : Google Scholar : PubMed/NCBI
4	Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S and Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 19:1001–1007. 2001. View Article : Google Scholar : PubMed/NCBI
5	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA: Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
6	Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, et al: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet. 377:127–138. 2011. View Article : Google Scholar : PubMed/NCBI
7	Baker J: Genomic Health, Inc. Pharmacoqenomics. 8:397–399. 2007. View Article : Google Scholar
8	Zhan Y, Guo W, Zhang Y, Wang Q, Xu XJ and Zhu L: A five-gene signature predicts prognosis in patients with kidney renal clear cell carcinoma. Comput Math Methods Med. 2015:8427842015. View Article : Google Scholar : PubMed/NCBI
9	De Melo J and Tang D: Elevation of SIPL1 (SHARPIN) increases breast cancer risk. PLoS One. 10:e01275462015. View Article : Google Scholar : PubMed/NCBI
10	Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA. 98:1176–1181. 2001. View Article : Google Scholar : PubMed/NCBI
11	Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62:4722–4729. 2002.PubMed/NCBI
12	Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, et al: Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 14:4376–4386. 2003. View Article : Google Scholar : PubMed/NCBI
13	Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, et al: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65:10602–10612. 2005. View Article : Google Scholar : PubMed/NCBI
14	Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M and Longacre TA: Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 96:684–694. 2005. View Article : Google Scholar : PubMed/NCBI
15	Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS and Cramer DW: Prostasin, a potential serum marker for ovarian cancer: Indentification through microarray technology. J Natl Cancer Inst. 93:1458–1464. 2001. View Article : Google Scholar : PubMed/NCBI
16	Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA and Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 23:7911–7918. 2005. View Article : Google Scholar : PubMed/NCBI
17	Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, et al: LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 63:1700–1710. 2014. View Article : Google Scholar : PubMed/NCBI
18	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
19	Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M and Steren A: National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer. 72:3007–3011. 1993. View Article : Google Scholar : PubMed/NCBI
20	Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR and Seamon LG: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
21	McCluggage WG: Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology. 43:420–432. 2011. View Article : Google Scholar : PubMed/NCBI
22	Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, et al: MANF: A new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci. 20:173–188. 2003. View Article : Google Scholar : PubMed/NCBI
23	Apostolou A, Shen Y, Liang Y, Luo J and Fang S: Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res. 314:2454–2467. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lindahl M, Danilova T, Palm E, Lindholm P, Võikar V, Hakonen E, Ustinov J, Andressoo JO, Harvey BK, Otonkoski T, et al: MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell Rep. 7:366–375. 2014. View Article : Google Scholar : PubMed/NCBI
25	Palgi M, Greco D, Lindström R, Auvinen P and Heino TI: Gene expression analysis of Drosophilaa Manf mutants reveals perturbations in membrane traffic and major metabolic changes. BMC Genomics. 13:1342012. View Article : Google Scholar : PubMed/NCBI
26	Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI
27	Yang YM, Yang Y, Dai WW, Li XM, Ma JQ and Tang LP: Genistein-induced apoptosis is mediated by endoplasmic reticulum stress in cervical cancer cells. Eur Rev Med Pharmacol Sci. 20:3292–3296. 2016.PubMed/NCBI
28	Yeh TC, Chiang PC, Li TK, Hsu JL, Lin CJ, Wang SW, Peng CY and Guh JH: Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem Pharmacol. 73:782–792. 2007. View Article : Google Scholar : PubMed/NCBI
29	El Jamal SM, Taylor EB, Elmageed Abd ZY, Alamodi AA, Selimovic D, Alkhateeb A, Hannig M, Hassan SY, Santourlidis S, Friedlander PL, et al: Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways. Cell Division. 11:112016. View Article : Google Scholar : PubMed/NCBI
30	Chen L, Feng L, Wang X, Du J, Chen Y, Yang W, Zhou C, Cheng L, Shen Y, Fang S, et al: Mesencephalic astrocyte-derived neurotrophic factor is involved in inflammation by negatively regulating the NF-κB pathway. Sci Rep. 5:81332015. View Article : Google Scholar : PubMed/NCBI
31	Rossman KL, Der CJ and Sondek J: GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 6:167–180. 2005. View Article : Google Scholar : PubMed/NCBI
32	Meller N, Irani-Tehrani M, Kiosses WB, Del Pozo MA and Schwartz MA: Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins. Nat Cell Biol. 4:639–647. 2002. View Article : Google Scholar : PubMed/NCBI
33	Gadea G and Blangy A: Dock-family exchange factors in cell migration and disease. Eur J Cell Biol. 93:466–477. 2014. View Article : Google Scholar : PubMed/NCBI
34	Cook DR, Rossman KL and Der CJ: Rho guanine nucleotide exchange factors: Regulators of Rho GTPase activity in development and disease. Oncogene. 33:4021–4035. 2014. View Article : Google Scholar : PubMed/NCBI
35	Côté JF and Vuori K: Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. J Cell Sci. 115:4901–4913. 2002. View Article : Google Scholar : PubMed/NCBI
36	Nishikimi A, Meller N, Uekawa N, Isobe K, Schwartz MA and Maruyama M: Zizimin2: A novel, DOCK180-related Cdc42 guanine nucleotide exchange factor expressed predominantly in lymphocytes. FEBS Lett. 579:1039–1046. 2005. View Article : Google Scholar : PubMed/NCBI
37	Lin Q, Yang W, Baird D, Feng Q and Cerione RA: Identification of a DOCK180-related guanine nucleotide exchange factor that is capable of mediating a positive feedback activation of Cdc42. J Biol Chem. 281:35253–35262. 2006. View Article : Google Scholar : PubMed/NCBI
38	Sakabe I, Asai A, Iijima J and Maruyama M: Age-related guanine nucleotide exchange factor, mouse Zizimin2, induces filopodia in bone marrow-derived dendritic cells. Immun Ageing. 9:22012. View Article : Google Scholar : PubMed/NCBI
39	Jing YY, Han ZP, Sun K, Zhang SS, Hou J, Liu Y, Li R, Gao L, Zhao X, Zhao QD, et al: Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 10:982012. View Article : Google Scholar : PubMed/NCBI
40	Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, Zhu JH, Yan B, Wei JJ, Zhang GM and Feng ZH: Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration. Breast Cancer Res Treat. 133:853–863. 2012. View Article : Google Scholar : PubMed/NCBI
41	Rakhesh M, Cate M, Vijay R, Shrikant A and Shanjana A: A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells. Oncoimmunology. 1:1495–1506. 2012. View Article : Google Scholar : PubMed/NCBI
42	Almstrup K, Leffers H, Lothe RA, Skakkebaek NE, Sonne SB, Nielsen JE, Rajpert-De Meyts E and Skotheim RI: Improved gene expression signature of testicular carcinoma in situ. Int J Androl. 30:292–302. 2007. View Article : Google Scholar : PubMed/NCBI
43	Pontén F, Jirström K and Uhlen M: The human protein atlas-a tool for pathology. J Pathol. 216:387–393. 2008. View Article : Google Scholar : PubMed/NCBI